Online inquiry

IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12354MR)

This product GTTS-WQ12354MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12354MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13123MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ5258MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ5344MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ9834MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ3707MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ2661MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ14042MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ383MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW